Form 4: Immunovant Chief Legal Officer Sells Shares to Cover Tax Obligations

Immunovant's Chief Legal Officer, Mark S. Levine, sold 3,650 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold 3,650 shares of common stock on November 20, 2024.
• The sale was executed at a weighted average price of $25.45 per share.
• The shares were sold to cover tax withholding obligations related to the vesting of 7,051 restricted stock units (RSUs).
• The sale was not a discretionary transaction by Mr. Levine but was mandated by Immunovant's policy to cover tax obligations through a 'sell to cover' transaction.
• The shares were sold in multiple transactions at prices ranging from $24.91 to $25.81 per share.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for company executives who receive stock-based compensation. It is common for companies to have 'sell to cover' policies to manage tax obligations.

Comparison to Industry Standards

• Many companies use restricted stock units as part of executive compensation packages.
• It is standard practice for companies to have policies in place to manage the tax implications of vesting RSUs, often through 'sell to cover' mechanisms.
• The price range of $24.91 to $25.81 per share is within the normal range of market fluctuations for a company like Immunovant.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but this is a routine transaction and not expected to have a significant effect.

Key Dates

Keywords

Immunovant, insider trading, Form 4, stock sale, restricted stock units, tax obligations, Mark S. Levine, IMVT, Chief Legal Officer